Summit Corporate Services

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of oncology therapies, specifically its lead candidate ivonescimab (SMT-112). Ivonescimab is a novel bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), aiming to combine immunotherapy with anti-angiogenesis in a single molecule. The company secured rights to ivonescimab in North America, Europe, and other territories through a landmark licensing agreement with Akeso Biopharma. Led by the former management team of Pharmacyclics, Summit is currently advancing ivonescimab through multiple Phase 3 clinical trials for non-small cell lung cancer (NSCLC). The company operates through several subsidiaries, including Summit Corporate Services, which provides administrative and management support for its global operations. This strategic focus on bispecific antibodies represents a significant pivot from the company's historical work in infectious diseases and rare genetic disorders.